Plus: ACOG recommends salpingectomy during hysterectomy, post-Dobbs abortion fears did not materialize, and a study examines alcohol use during pregnancy.
Essity spent $284 million on period care brands, impacting the competitive landscape for menstrual health operators. Channel Medsystems secured $30 million in an ongoing Series C round for heavy menstrual bleeding treatment, bringing new clinical options to gynecologists. These financial movements occur as the American College of Obstetricians and Gynecologists updated guidance recommending routine bilateral salpingectomy during hysterectomy to prevent ovarian cancer, changing best practices for clinicians. Five takes inside, plus a quick-hits roundup.
VIA FutureFemHealth
Essity agreed to a US$284 million acquisition of Kenvue’s Carefree, Sempre Livre, and o.b. period care brands in Brazil. Separately, Channel Medsystems secured US$30 million in an ongoing Series C round led by InnovaHealth Partners to expand its Cerene non-hormonal cryotherapy treatment for heavy menstrual bleeding. TowerBrook also invested in cycle care brand Rael, supporting product and international expansion. These investments highlight continued financial interest in menstrual health and period care solutions.
Read the full story →
— The Luteal Editorial Team
VIA Contemporary OB/GYN
The American College of Obstetricians and Gynecologists (ACOG) updated guidance now recommends routine bilateral salpingectomy during hysterectomy and other surgeries to prevent ovarian cancer. This revision provides clinicians new best practices for gynecological procedures.
Read the full story →
— The Luteal Editorial Team
VIA JAMA Network
A study examines trends and correlates of current alcohol use, binge drinking, and heavy drinking among pregnant women in the US. The research covers data from 2011 to 2024. This research provides critical data for maternal health operators and clinicians.
Read the full story →
— The Luteal Editorial Team
VIA Contemporary OB/GYN
A panel reviews two-year outcomes from a major open-label extension trial for Relugolix Combination Therapy. This therapy treats endometriosis pain.
Read the full story →
— The Luteal Editorial Team
VIA STAT News
Many post-Dobbs abortion fears, including predictions of falling abortion rates and worsening infant and maternal deaths, did not materialize. The author initially assumed abortion rates would decline, infant and maternal mortality would increase, and doctors in states with abortion restrictions would relocate. However, these specific outcomes did not manifest as anticipated.
Read the full story →
— The Luteal Editorial Team